Best News Fron Recent RNS17 Nov 2019 16:05
Commenting on the successful Placing, Dr Markku Jalkanen, CEO of Faron, said: "We are very pleased to have received such a tremendous support from new and existing shareholders, employees and Company directors in this transaction. We are very happy to have a significant number of new Nordic shareholders. This financing will allow us to further progress our clinical programme on Clevegen with a view to clarifying its full potential, either alone or in combination with existing cancer treatments. This is very important as many, if not all, cancer patients have reduced immune capacity to defend them against cancer spread and may potentially be focal information in terms of specifying our goals for the ongoing partnering discussions."